Celldex Therapeutics Reports Q3 2026 GAAP EPS of -$0.96, Exceeding Estimates
Celldex Therapeutics (CLDX) reported third-quarter earnings for the period ending September 30, 2026, posting a GAAP EPS of -$0.96. This result surpassed analyst expectations by $0.07. The company reported no material revenue for the third quarter or the first nine months of 2026. The report follows recent clinical developments regarding Barzolvolimab, specifically positive Phase 3 results for Chronic Spontaneous Urticaria (CSU). Despite the earnings beat, market volatility has been noted following previous discussions surrounding late-stage trial data and the company's historical performance.
Tickers: $CLDX
Topics: earnings beat GAAP EPS revenue report